Name | Type | Posted | Actions |
|---|---|---|---|
A0002 HT9402-26-Q-9101 Amend.pdf | Jan 8, 2026 | ||
A0001 February 2026 PandT Meeting Reporting.xlsx | XLSX | Dec 4, 2025 | |
A0001 HT9402-26-Q-9101 Amend.pdf | Dec 4, 2025 | ||
RFQ HT9402-26-Q-9101 CR.pdf | Nov 18, 2025 | ||
https://health.mil/PandT | LINK | Nov 18, 2025 | |
NDC Price List-Antihemophilic Agents - Non-factor Agents.xlsx | XLSX | Nov 18, 2025 | |
NDC Price List FAQ Class Review.pdf | Nov 18, 2025 | ||
NDC Price List-Oncological Agents - Myelofybrosis.xlsx | XLSX | Nov 18, 2025 |
Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
Contact and place of performance
Tracy Banks
San Antonio, TX 78230
USA
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical e...
View morehe RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9101. Pre-quotation teleconference is on November 20, 2025. Details are stated in Part 2.4. Pre-Quotation Teleconference.
The Defense Health Agency Aurora, on behalf of the TRICARE Management Activity, is soliciting quotes for pharmaceutical agents to support the Department of Defense (DoD) Pharmacy Uniform Formulary. Pursuant to 10 U.S.C. § 1074g and 32 CFR Section 199.21, the DoD Pharmacy and Therapeutics (P&T) Committee evaluates the clinical and cost effectiveness of drugs to determine their classification as generic, formulary, Basic Core Formulary, Extended Core Formulary, or non-formulary. This specific solicitation, identified under number HT9402-26-Q-9101, focuses on oncological agents for myelofibrosis, including Inrebic, Jakafi, Ojjaara, and Vonjo. The agency intends to award Uniform Formulary Blanket Purchase Agreements (UF BPA) and Uniform Formulary Additional Discount Program (UF ADP) agreements based on the resulting formulary decisions.
This requirement is classified under NAICS 325412 for Pharmaceutical Preparation Manufacturing and PSC 6505 for Drugs and Biologicals. Performance is centered in San Antonio, Texas, with a response deadline of January 16, 2026. The procurement process involves eight total attachments, including multiple amendments and price lists for various agents. Tracy Banks serves as the point of contact for this solicitation. Detailed instructions regarding the submission of quotes and the structure of the UF BPA and UF ADP appendices are contained within the primary Request for Quotation document.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.